MiNK Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2025, on August 14, 2025. The company reported a strengthened balance sheet and expanded funding to advance both oncology and immunology programs.
CEO Jennifer Buell, Ph.D., stated that the company's cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-iNKTs in GvHD, will enable substantial clinical program advancements. These financial improvements extend the company's cash runway beyond mid-2026.
The second quarter saw high-impact clinical results and the publication of key clinical findings, further demonstrating the power of MiNK's platform. These strategic and financial milestones position the company for continued progress in its therapeutic areas.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.